8,546 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Illumine Investment Management LLC

Illumine Investment Management LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,546 shares of the biotechnology company’s stock, valued at approximately $3,015,000. United Therapeutics comprises approximately 2.5% of Illumine Investment Management LLC’s investment portfolio, making the stock its 10th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics in the 4th quarter valued at about $25,000. Brooklyn Investment Group acquired a new position in United Therapeutics in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in United Therapeutics in the 3rd quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in United Therapeutics in the 3rd quarter valued at about $111,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.5 %

UTHR opened at $323.62 on Friday. The firm has a market cap of $14.45 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The business’s 50 day moving average is $360.44 and its two-hundred day moving average is $360.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company posted $4.36 earnings per share. Equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday. LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insider Activity

In related news, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 124,164 shares of company stock valued at $45,278,893. Company insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.